B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Price:
11.98
HKD
-0.33%
Market Closed
Market Cap:
4.8B
HKD
Income Statement
Earnings Waterfall
Biocytogen Pharmaceuticals Beijing Co Ltd
Biocytogen Pharmaceuticals Beijing Co Ltd
|
Revenue
|
980.5m
CNY
|
|
Cost of Revenue
|
-218.9m
CNY
|
|
Gross Profit
|
761.5m
CNY
|
|
Operating Expenses
|
-611m
CNY
|
|
Operating Income
|
150.5m
CNY
|
|
Other Expenses
|
-117m
CNY
|
|
Net Income
|
33.5m
CNY
|
Income Statement
Biocytogen Pharmaceuticals Beijing Co Ltd
Biocytogen Pharmaceuticals Beijing Co Ltd
Currency: CNY
Millions
TTM
| Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | ||
|---|---|---|---|---|---|
| Revenue | |||||
| Interest Expense |
23
|
24
|
29
|
32
|
|
| Revenue |
632
N/A
|
717
+14%
|
801
+12%
|
980
+22%
|
|
| Gross Profit | |||||
| Cost of Revenue |
(171)
|
(211)
|
(224)
|
(219)
|
|
| Gross Profit |
460
N/A
|
506
+10%
|
576
+14%
|
762
+32%
|
|
| Operating Income | |||||
| Operating Expenses |
(935)
|
(812)
|
(724)
|
(611)
|
|
| Selling, General & Administrative |
(329)
|
(349)
|
(347)
|
(311)
|
|
| Research & Development |
(619)
|
(474)
|
(388)
|
(324)
|
|
| Other Operating Expenses |
14
|
11
|
11
|
24
|
|
| Operating Income |
(474)
N/A
|
(306)
+35%
|
(148)
+52%
|
151
N/A
|
|
| Pre-Tax Income | |||||
| Interest Income Expense |
23
|
(14)
|
(35)
|
(62)
|
|
| Non-Reccuring Items |
(6)
|
16
|
22
|
14
|
|
| Total Other Income |
(61)
|
(76)
|
(77)
|
(60)
|
|
| Pre-Tax Income |
(518)
N/A
|
(380)
+27%
|
(238)
+37%
|
43
N/A
|
|
| Net Income | |||||
| Tax Provision |
(1)
|
(3)
|
(6)
|
(9)
|
|
| Income from Continuing Operations |
(519)
|
(383)
|
(244)
|
34
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(519)
N/A
|
(383)
+26%
|
(244)
+36%
|
34
N/A
|
|
| EPS (Diluted) |
-1.3
N/A
|
-0.96
+26%
|
-0.61
+36%
|
0.08
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
